1.16
+0.1503(+14.88%)
Currency In USD
| Previous Close | 1.01 |
| Open | 1.03 |
| Day High | 1.18 |
| Day Low | 1.02 |
| 52-Week High | 4.6 |
| 52-Week Low | 0.52 |
| Volume | 1.32M |
| Average Volume | 737,362 |
| Market Cap | 98.36M |
| PE | -0.46 |
| EPS | -2.51 |
| Moving Average 50 Days | 0.88 |
| Moving Average 200 Days | 1.06 |
| Change | 0.15 |
If you invested $1000 in Sutro Biopharma, Inc. (STRO) since IPO date, it would be worth $76.34 as of October 20, 2025 at a share price of $1.16. Whereas If you bought $1000 worth of Sutro Biopharma, Inc. (STRO) shares 5 years ago, it would be worth $96.13 as of October 20, 2025 at a share price of $1.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
GlobeNewswire Inc.
Sep 29, 2025 9:05 PM GMT
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
GlobeNewswire Inc.
Jul 22, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has e
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointme